Since Lloyd J Old’s original proposal that specific antigens were associated with tumors [1], the field of cancer immunotherapy has made significant advances to improve efficacy, including the use of high-dose IL-2 therapy, cloning tumor antigens, and identifying tumor-reactive T cells [2,3,4,5,6,7,8]. This evidence concerns the gene IL2 and neoplasm.